Compare funds
Pick up to 10 funds. Compare funds from the same category for a fair reading.
Growth of ₹10,000
Basics
| Nippon India ETF Nifty Midcap 150 | Nippon India Nifty Pharma ETF | |
|---|---|---|
| Category | Equity ETFs | Equity ETFs |
| Plan | Direct | Direct |
| Fund house | Nippon India | Nippon India |
| NAV | ₹235.6824 | ₹29.1863 |
| NAV date | 20 Nov 2026 | 20 Nov 2026 |
| History | 7.8 years | 5.4 years |
| Expense ratio | 0.3% | 0.2% |
| Stars | Not rated | Not rated |
| Growth Score | — | — |
Returns
| Nippon India ETF Nifty Midcap 150 | Nippon India Nifty Pharma ETF | |
|---|---|---|
| 1 month | +5.97% | +10.82% |
| 3 months | −2.55% | +7.43% |
| 6 months | +1.72% | +14.54% |
| YTD | +2.66% | +25.40% |
| 1 year | +2.08% | +25.57% |
| 3 years (CAGR) | +13.87% | +22.02% |
| 5 years (CAGR) | +14.66% | +16.60% |
| 10 years (CAGR) | — | — |
| Since launch | +18.99% | +14.02% |
Risk
| Nippon India ETF Nifty Midcap 150 | Nippon India Nifty Pharma ETF | |
|---|---|---|
| Volatility | 18.3% | 15.0% |
| Downside volatility | 12.4% | 9.0% |
| Sharpe | 0.40 | 1.04 |
| Sortino | 0.59 | 1.72 |
| Calmar | 0.66 | 1.33 |
| Return / risk | 0.76 | 1.47 |
| Deepest fall | −38.35% | −20.98% |
| Days to recover | 228 | 136 |
| Below its high | −3.21% | −1.75% |
Against benchmark
| Nippon India ETF Nifty Midcap 150 | Nippon India Nifty Pharma ETF | |
|---|---|---|
| Alpha | −0.29% | −0.23% |
| Beta | 1.00 | 1.00 |
| R² | 100.0% | 100.0% |
| Up capture | 99.4% | 99.6% |
| Down capture | 100.5% | 100.6% |
| Tracking error | 0.0% | 0.0% |
| Information ratio | −42.55 | −42.00 |
| Treynor | 0.06 | 0.14 |
Consistency
| Nippon India ETF Nifty Midcap 150 | Nippon India Nifty Pharma ETF | |
|---|---|---|
| Best 1-year | +116.74% | +65.21% |
| Middle 1-year | +14.06% | +13.46% |
| Worst 1-year | −33.73% | −15.30% |
| 1-year periods with a loss | 11.6% | 25.8% |
| Middle 3-year | +24.17% | +20.51% |
| Positive months | 66.7% | 61.1% |
| Best day | +3.95% | +3.64% |
| Worst day | −7.10% | −4.03% |
| Worst 5% day | −2.00% | −1.62% |
| Positive days | 57.1% | 54.4% |
| NAVs a year | 248 | 248 |
SIP of ₹10,000 a month
| Nippon India ETF Nifty Midcap 150 | Nippon India Nifty Pharma ETF | |
|---|---|---|
| 5-year XIRR | +14.79% | +20.60% |
| 5-year value | ₹8,75,434 | ₹10,11,738 |
| 3-year XIRR | +7.85% | +19.58% |
| 1-year XIRR | +6.18% | +34.31% |
Holdings overlap i
| Nippon India ETF Nifty Midcap 150 | Nippon India Nifty Pharma ETF | |
|---|---|---|
| Nippon India ETF Nifty Midcap 150 Direct · filing Oct 2026 | — | 9% |
| Nippon India Nifty Pharma ETF Direct · filing Oct 2026 | 9% | — |
Share of money in the same stocks, by weight. Above 50% means much of one fund repeats the other.
Held by all of them
| Stock | Nippon India ETF Nifty Midcap 150 | Nippon India Nifty Pharma ETF |
|---|---|---|
| Laurus Labs Limited | 2.41% | 9.26% |
| Lupin Limited | 1.25% | 4.83% |
| Aurobindo Pharma Limited | 1.19% | 4.59% |
| Glenmark Pharmaceuticals Limited | 0.89% | 3.42% |
| Alkem Laboratories Limited | 0.79% | 3.05% |
| Mankind Pharma Limited | 0.73% | 2.79% |
| IPCA Laboratories Limited | 0.69% | 2.65% |
| Biocon Limited | 0.63% | 2.42% |
| Ajanta Pharma Limited | 0.41% | 1.58% |
| Abbott India Limited | 0.34% | 1.32% |
Sectors and company size
| Nippon India ETF Nifty Midcap 150 | Nippon India Nifty Pharma ETF | |
|---|---|---|
| Large companies | 5.9% | 45.3% |
| Mid companies | 90.7% | 47.1% |
| Small companies | 2.5% | 7.6% |
| Top 10 holdings | 18.4% | 78.6% |
| Largest sector | Pharmaceuticals & Biotechnology 10% | Pharmaceuticals & Biotechnology 100% |